---
layout: post
title: "Considerations for Including Tissue Biopsies in Clinical Trials; Draft Guidance for Industry, Investigators, Institutions, and Institutional Review Boards; Availability"
date: 2026-02-04 21:49:32 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-31536
original_published: 2025-01-07 00:00:00 +0000
significance: 8.00
---

# Considerations for Including Tissue Biopsies in Clinical Trials; Draft Guidance for Industry, Investigators, Institutions, and Institutional Review Boards; Availability

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** January 07, 2025 00:00 UTC
**Document Number:** 2024-31536

## Summary

The Food and Drug Administration (FDA or Agency) and the Office for Human Research Protections (OHRP) are announcing the availability of a draft guidance for industry, clinical investigators, institutions, and institutional review boards (IRBs) entitled "Considerations for Including Tissue Biopsies in Clinical Trials." This guidance provides recommendations regarding considerations for tissue biopsies that may be conducted in adults and in children as part of clinical trials evaluating investigational medical products and/or that are conducted or supported by the Department of Health and Human Services (HHS).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/01/07/2024-31536/considerations-for-including-tissue-biopsies-in-clinical-trials-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2024-31536

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
